StockData
Gain Therapeutics, Inc. logo

Gain Therapeutics, Inc. (GANX) shareholders

GANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 3/30
$1.18+0.24 (+25.51%)

Close on Nov 17, 2026Market cap $51.50MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
21.1%
9M of 44M shares
Institutional holders
50
12 new, 4 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of GANXValueChange% of portfolio
Marshall Wace, Llp1,923,5464.41%$3.90M+153,7580.00%
Cambridge Investment Research Advisors, Inc.1,137,2902.61%$2.31M+568,6450.00%
Potomac Capital Management, Inc.946,4002.17%$1.92M−62,2001.31%
Gsa Capital Partners Llp632,1311.45%$1.28M+319,6640.08%
Jones Financial Companies Lllp608,5921.39%$1.07M−23,0230.00%
DME Capital Management, LP566,1301.30%$1.15M–0.03%
Vanguard Capital Management LLC480,2691.10%$974.95K+80,3830.00%
Geode Capital Management, LLC453,5011.04%$921.37K+6,1590.00%
BlackRock, Inc.274,9570.63%$558.16K+49,9110.00%
Vanguard Fiduciary Trust Co231,5340.53%$470.01K+1,5550.00%
UBS Group AG215,0120.49%$436.48K−5,4770.00%
Stratos Wealth Partners, LTD.200,0000.46%$406.00K+68,3790.00%
Cresset Asset Management, LLC160,0000.37%$324.80K–0.00%
State Street Corp157,5370.36%$319.80K–0.00%
Citadel Advisors LLC154,5240.35%$313.68K+129,6240.00%
Squarepoint Ops LLC136,3590.31%$276.81KNew0.00%
Morgan Stanley125,9720.29%$255.72K−13,6800.00%
LPL Financial LLC117,2510.27%$238.02K+13,0000.00%
Northern Trust Corp97,0130.22%$196.94K−16,9840.00%
Susquehanna International Group, Llp78,2060.18%$158.76K−353,0610.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026509M21.1%12 / 159 / 42M1M
Q1 2026428M18.8%10 / 910 / 152M1M
Q4 2025488M18.5%21 / 153 / 105M1M
Q3 2025384M10.0%9 / 144 / 61M0M
Q2 2025354M8.7%6 / 115 / 41M0M
Q1 2025333M6.4%10 / 122 / 21M0M
Q4 2024252M4.5%10 / 82 / 41M0M
Q3 2024192M3.8%3 / 54 / 111M2M
Q2 2024283M7.0%8 / 97 / 62M1M
Q1 2024262M4.3%6 / 116 / 31M0M
Q4 2023242M3.5%3 / 86 / 30M0M
Q3 2023242M3.5%2 / 96 / 20M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

12 funds held GANX in Q2 2026, 60% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of GANXValue% of fundAs of
Vanguard Extended Market Index Fund430,9020.99%$874.73K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund207,1060.47%$403.86K0.00%May 31, 2026
iShares Micro-Cap ETF144,1590.33%$292.64K0.02%Jun 30, 2026
Fidelity Total Market Index Fund57,3350.13%$111.80K0.00%May 31, 2026
Fidelity Series Total Market Index Fund55,6360.13%$108.49K0.00%May 31, 2026
Ultra-Small Company Market Fund30,0040.07%$60.91K0.04%Jun 30, 2026
Fidelity Nasdaq Composite Index Fund28,6290.07%$55.83K0.00%May 31, 2026
1290 VT Micro Cap Portfolio9,7300.02%$19.75K0.01%Jun 30, 2026
Total Stock Market Index Trust9660.00%$1.96K0.00%Jun 30, 2026
Blackstone Alternative Multi-Strategy Fund-7,200-0.02%-$14.62K-0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Gene MackCEO, President, Director14,4000.03%Mar 26, 2026
Jeanette WeidnerSee Remarks––Oct 30, 2026
Gianluca FuggettaSee Remark––Mar 26, 2026
Dov A. Goldstein MdDirector––Jul 17, 2026
Hans Peter HaslerDirector––Jul 17, 2026
Claude NicaiseDirector––Jul 17, 2026
Jeffrey Scott RileyDirector30,0000.07%Jul 17, 2026
Gwen A. MelincoffDirector––Jul 17, 2026
Khalid IslamDirector930,7842.13%Jul 17, 2026
Eric I. RichmanDirector304,4580.70%Jun 25, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Gene Mack
CFO and Interim CEO
Aug 9, 2024Buy+14,400$1.01$14.54K14,400
Khalid Islam
Executive Chairman, Director
Aug 9, 2024Buy+50,000$1.00$50.00K50,000
Eric I. Richman
Director
Jul 1, 2024Buy+12,000$1.21$14.52K289,629
Eric I. Richman
Director
Jul 1, 2024Buy+5,000$1.23$6.15K277,629
Jeffrey Scott Riley
Director
Mar 28, 2024Buy+30,000$3.86$115.80K30,000
Matthias Alder
Chief Executive Officer, Director
Mar 26, 2024Option exercise+637––27,225
Matthias Alder
Chief Executive Officer, Director
Mar 26, 2024Option exercise+18,750––25,763
Matthias Alder
Chief Executive Officer, Director
Mar 26, 2024Option exercise+825––26,588
Matthias Alder
Chief Executive Officer, Director
Mar 26, 2024Tax withholding−6,085$4.06$24.71K21,140
Matthias Alder
Chief Executive Officer, Director
Dec 21, 2023Sale−206$2.46$5075,286
Matthias Alder
Chief Executive Officer, Director
Dec 20, 2023Option exercise+637––5,492
Matthias Alder
Chief Executive Officer, Director
Dec 7, 2023Sale−1,820$2.50$4.55K4,855
Matthias Alder
Chief Executive Officer, Director
Oct 1, 2023Option exercise+825––6,675
Matthias Alder
Chief Executive Officer, Director
Sep 20, 2023Option exercise+2,550––5,850
Eric I. Richman
Director
Sep 20, 2023Option exercise+54,900––272,629
Matthias Alder
Chief Executive Officer, Director
Jul 1, 2023Option exercise+3,300––3,300
Eric I. Richman
CHIEF EXECUTIVE OFFICER, Director
May 25, 2022Buy+2,482$2.58$6.40K217,729
Eric I. Richman
CHIEF EXECUTIVE OFFICER, Director
May 20, 2022Buy+9,256$2.83$26.19K215,247
Eric I. Richman
CHIEF EXECUTIVE OFFICER, Director
May 19, 2022Buy+4,000$2.71$10.84K205,991
Salvatore Calabrese
CHIEF FINANCIAL OFFICER
May 19, 2022Buy+3,000$2.70$8.10K3,000
Salvatore Calabrese
CHIEF FINANCIAL OFFICER
May 19, 2022Buy+3,000$8100.00$24.30M–
Eric I. Richman
Chief Executive Officer, Director
Aug 16, 2021Buy+4,922$7.87$38.74K216,820
Eric I. Richman
Director
Aug 16, 2021Option exercise+4,922$7.87$38.74K216,820

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
9.19%
4M shares short
Days to cover
5.5
At 1M shares a day
Change since last report
+21.9%
From 3M shares
Short volume, 20 days
55.1%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Gain Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 5,043 shares on Oct 7, 2026 over the last 90 days.

See a number that looks wrong?